Study M166
Study name | Zheng X 2014 |
Title | Peripheral immunomodulation with ginsenoside Rg1 ameliorates neuroinflammation-induced behavioral deficits in rats |
Overall design | In this study, the authors reported that neuroinflammation-induced behavioral abnormality could be effectively attenuated with immunomodulatory agents that need not to gain brain penetration. In a rat model with intracerebral lipopolysaccharide (LPS) challenge, the authors validated that ginsenoside Rg1 (Rg1), a well established anti-inflammatory agent, was unable to produce a direct action in the brain. Rats were divided into the following 6 groups (n = 6 in each group): (1) control group (sham saline 5 uL), (2) LPS group (LPS 5 ug), (3) LPS + low dose of Rg1 group (LPS 5 ug plus Rg1 treatment at the dose of 10 mg/kg), (4) LPS + high dose of Rg1 group (LPS 5 ug plus Rg1 treatment at the dose of 30 mg/kg, (5) LPS + minocycline group (LPS 5 ug plus minocycline treatment at the dose of 30 mg/kg), and (6) high dose of Rg1 group (Rg1 treatment at the dose of 30 mg/kg). LPS and saline were administered via i.c.v. injection. Rg1 and minocycline were administered intraperitoneally for 3 consecutive days (once daily). The quantification of plasma corticosterone, and 5-HT with its downstream metabolites 5-hydroxyindoleacetic acid (5-HIAA), kynurenine (KYN) and kynurenic acid (KA) in the rat brain cortex were performed by LC-MS platform. The ratio of 5-HIAA/5-HT and KA/KYN was then calculated to reflect the metabolic turnover of 5-HT and the balance of KA pathway, respectively. |
Study Type | Type1; Type2; Type3; |
Data available | Unavailable |
Organism | Rat; Wistar rat; |
Categories of depression | Animal model; Lipopolysaccharide induced depression model; Lipopolysaccharide induced depression model; Healthy individuals; Healthy individuals; Healthy individuals; |
Criteria for depression | Sucrose preference test |
Sample size | 36 |
Tissue | Peripheral; Blood; Plasma; Central; Brain; Cerebral cortex; |
Platform | MS-based; LC-MS: LC-MS (Shimazu, Nakagyo-ku, Kyoto, Japan); |
PMID | |
DOI | |
Citation | Zheng X, Liang Y, Kang A, et al. Peripheral immunomodulation with ginsenoside Rg1 ameliorates neuroinflammation-induced behavioral deficits in rats. Neuroscience 2014;256:210-22. |
Metabolite |
